<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275349</url>
  </required_header>
  <id_info>
    <org_study_id>CFH 2018-1-4191</org_study_id>
    <nct_id>NCT04275349</nct_id>
  </id_info>
  <brief_title>Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE</brief_title>
  <acronym>TRACE</acronym>
  <official_title>Trial of pRehospital Intervention With trAditional Chinese Medicine for Acute strokE: A Mixed Methods Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Emergency Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre for Evidence Based Chinese Medicine, Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Shijitan Hospital,Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Fengtai Youanmen Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Jiangong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chaoyang Emergency Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chaoyang Integrative Medicine Emergency Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fangshan Hospital，Beijing University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Civil Aviation General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Fangshan District,Beijing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chinese Medicine Hospital-Pinggu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Pinggu District Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to observe whether Xingnaojing, intravenously administered
      within 24 hours of symptom onset on pre-hospital emergency ambulance, improves the Early
      neurological deterioration of acute stroke at 3 days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TRACE is a multicenter, registry observational study. Xingnaojing injection is the only
      essential traditional chinese medicine on emergency ambulance used for acute stroke.The
      primary hypothesis of this trial is that Xingnaojing used for acute stroke within 24 hours of
      symptom onset on ambulance will improve the Early neurological deterioration of acute stroke
      at 3 days. All suspected acute stroke participants will be registered once they are taken on
      the ambulance. The primary outcome will be determined at 3 days.Besides, there will be a
      quantitative interview with emergency doctors about their knowledge and attitude on
      Xingnaojing for acute stroke patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Early neurological deterioration（change between baseline and 3 days)</measure>
    <time_frame>3 days</time_frame>
    <description>The early neurologic deterioration is defined as an increase of 1 points or more in the National Institute of Health Stroke Scale (NIHSS) score between baseline and 3 days. The NIHSS score ranges from 0 (best score) to 42 (worst score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke related deaths and deaths from any cause</measure>
    <time_frame>14 days during hospitalization</time_frame>
    <description>Rate of stroke related deaths and deaths from any cause during hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological impairment</measure>
    <time_frame>Baseline and day of discharge or 10 days</time_frame>
    <description>Evaluated by National Institute of Health Stroke Scale (NIHSS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk grade of cerebral hemorrhage</measure>
    <time_frame>Baseline and day of discharge or 10 days</time_frame>
    <description>Intracranial hemorrhage evaluated by Intracerebral Haemorrhage(ICH) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living</measure>
    <time_frame>30 days,60 days and 90 days</time_frame>
    <description>Activities of daily living will be measured by Barthel Index (BI)score at 30 days and 90 days.The Barthel Index score ranges from 0 (worst score) to 100 (best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients independent</measure>
    <time_frame>30 days,60 days and 90 days</time_frame>
    <description>The proportion of patients independent will be evaluated by modified Rankin Scale(mRS).The mRS score ranges from 0 (best score) to 6 (worst score).</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke</condition>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Acute Intracranial Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Exposure group(continuously)</arm_group_label>
    <description>xingnaojing injection will be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital or at hospital)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exposure group(uncontinuously)</arm_group_label>
    <description>xingnaojing injection will be intravenously administered within 24 hours of symptom onset for once (on prehospital ambulance )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Completely unexposed group</arm_group_label>
    <description>xingnaojing injection will not be intravenously administered within 24 hours of symptom onset until to third day (from prehospital ambulance to hospital)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incompletely unexposed group</arm_group_label>
    <description>xingnaojing injection will not be intravenously administered on ambulance but administered more than 24 hours of symptom onset at hospital</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xingnaojing injection within 24 hours of symptom onset</intervention_name>
    <description>intravenously administered Xingnaojing injection within 24 hours of symptom onset on ambulance or at hospital</description>
    <arm_group_label>Exposure group(continuously)</arm_group_label>
    <arm_group_label>Exposure group(uncontinuously)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        suspected acute stroke patient (call for emergency ambulance)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of suspected acute stroke；

          -  Symptom onset within 24 hours；

          -  Age ≥ 18 .

        Exclusion Criteria:

          -  Other conditions that lead to motor dysfunction (e.g., severe osteoarthrosis,
             rheumatoid arthritis);

          -  Other conditions that render outcomes or follow-up unlikely to be assessed; Known to
             be pregnant or breastfeeding;

          -  Non-acute stroke (result from Computed Tomography(CT) or Magnetic Resonance
             Imaging(MRI)).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital,Beijing University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Gao, MD</last_name>
    <phone>0086-010-84013209</phone>
    <email>gaoying973@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lingbo Kong, MD</last_name>
    <phone>008613167323987</phone>
    <email>klb1984@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Gao, MD</last_name>
      <phone>0086-010-84013209</phone>
      <email>gaoying973@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lingbo Kong, MD</last_name>
      <phone>0086-13167323987</phone>
      <email>klb1984@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 7, 2020</study_first_submitted>
  <study_first_submitted_qc>February 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ying Gao</investigator_full_name>
    <investigator_title>President of the Institute for Encephalopathy, Beijing University of Chinese Medicine</investigator_title>
  </responsible_party>
  <keyword>Registry</keyword>
  <keyword>Cohort study</keyword>
  <keyword>Mixed methods</keyword>
  <keyword>Prehospital</keyword>
  <keyword>Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

